Video
Dr. Levy on EGFR TKIs in Lung Cancer
Author(s):
Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.
Benjamin P. Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.
More agents have been approved in the field for patients with EGFR mutations within the past year, Levy explains, such as gefitinib. Prior to such approvals, treatment choices included erlotinib and afatinib. The combination of erlotinib plus bevacizumab is also being investigated in an ongoing US study.
There are also third-generation TKIs previously used for resistant disease that are now being studied in the frontline setting, Levy says.
<<<
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
